CVA Family Office LLC lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 43.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 155 shares of the medical research company’s stock after selling 120 shares during the period. CVA Family Office LLC’s holdings in IQVIA were worth $28,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in IQV. HighTower Advisors LLC lifted its stake in IQVIA by 2.4% during the first quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock worth $1,168,000 after purchasing an additional 118 shares during the last quarter. Prudential PLC bought a new stake in IQVIA during the first quarter worth about $741,000. Baird Financial Group Inc. lifted its stake in shares of IQVIA by 2.3% in the 1st quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock valued at $23,021,000 after acquiring an additional 2,201 shares during the last quarter. Parkside Financial Bank & Trust lifted its stake in shares of IQVIA by 59.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock valued at $90,000 after acquiring an additional 144 shares during the last quarter. Finally, Covestor Ltd lifted its stake in shares of IQVIA by 82.2% in the 1st quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock valued at $128,000 after acquiring an additional 250 shares during the last quarter. Institutional investors own 86.20% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on IQV. Credit Suisse Group reissued an “outperform” rating and issued a $265.00 target price on shares of IQVIA in a research note on Monday, February 13th. StockNews.com began coverage on IQVIA in a research note on Thursday. They issued a “hold” rating for the company. Cowen initiated coverage on IQVIA in a research note on Tuesday, December 6th. They issued an “outperform” rating for the company. Cowen initiated coverage on IQVIA in a research report on Tuesday, December 6th. They set an “outperform” rating and a $251.00 price target for the company. Finally, SVB Leerink reaffirmed an “outperform” rating on shares of IQVIA in a research report on Friday, January 27th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $256.81.
Insider Buying and Selling
IQVIA Stock Down 2.8 %
IQV stock opened at $190.89 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $165.75 and a fifty-two week high of $254.94. The business’s 50 day moving average price is $218.94 and its two-hundred day moving average price is $208.72. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.89 and a current ratio of 0.89. The company has a market capitalization of $35.53 billion, a price-to-earnings ratio of 33.43, a price-to-earnings-growth ratio of 1.97 and a beta of 1.40.
IQVIA (NYSE:IQV – Get Rating) last posted its earnings results on Friday, February 10th. The medical research company reported $2.78 earnings per share for the quarter, topping analysts’ consensus estimates of $2.76 by $0.02. IQVIA had a return on equity of 31.88% and a net margin of 7.57%. The firm had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.71 billion. During the same quarter in the prior year, the business earned $2.42 EPS. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. As a group, analysts forecast that IQVIA Holdings Inc. will post 9.46 earnings per share for the current fiscal year.
IQVIA Company Profile
IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.